NEOADJUVANT SYSTEMIC THERAPY FOR BREAST CANCER (RETROSPECTIVE AND PROSPECTIVE ANALYSIS)

There are presented the immediate and long-term results of neoadjuvant endocrine therapy versus chemotherapy in ER+ breast cancer and chemotherapy (carboplatin + taxane) at triple-negative tumor subtype. We marked a tendency of improving a 10-year disease-free survival at luminal A subtype in patients who received endocrine therapy compared with chemotherapy (72.8% vs. 53.9%; p=0.062). Only 5.9% of patients with ER+ /HER2+ co-expression, who received target therapy, reached complete regression (pCR). There was a greater frequency of pCR, among patients with triple-negative breast cancer who received neoadjuvant chemotherapy with paclitaxel + carboplatin.